These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 8932771)

  • 1. Leishmania major: targeting IL-4 in successful immunomodulation of murine infection.
    Wakil AE; Wang ZE; Locksley RM
    Exp Parasitol; 1996 Nov; 84(2):214-22. PubMed ID: 8932771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
    Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
    J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA; Ogunremi O; Menon JN
    Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LACK-reactive CD4+ T cells require autocrine IL-2 to mediate susceptibility to Leishmania major.
    Gumy A; Aseffa A; Rachinel N; Breton M; Otten L; Tacchini-Cottier F; Röcken M; Doyen N; Acha-Orbea H; Locksley RM; MacDonald HR; Launois P; Louis J
    Eur J Immunol; 2006 Jun; 36(6):1465-73. PubMed ID: 16637008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice.
    Biedermann T; Zimmermann S; Himmelrich H; Gumy A; Egeter O; Sakrauski AK; Seegmüller I; Voigt H; Launois P; Levine AD; Wagner H; Heeg K; Louis JA; Röcken M
    Nat Immunol; 2001 Nov; 2(11):1054-60. PubMed ID: 11600887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania.
    Al-Wabel MA; Tonui WK; Cui L; Martin SK; Titus RG
    Am J Trop Med Hyg; 2007 Dec; 77(6):1060-5. PubMed ID: 18165522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
    Webb JR; Kaufmann D; Campos-Neto A; Reed SG
    J Immunol; 1996 Dec; 157(11):5034-41. PubMed ID: 8943412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-gamma response and increased production of T helper 2 cytokines.
    Krishnan L; Guilbert LJ; Russell AS; Wegmann TG; Mosmann TR; Belosevic M
    J Immunol; 1996 Jan; 156(2):644-52. PubMed ID: 8543816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis.
    Bottrel RL; Dutra WO; Martins FA; Gontijo B; Carvalho E; Barral-Netto M; Barral A; Almeida RP; Mayrink W; Locksley R; Gollob KJ
    Infect Immun; 2001 May; 69(5):3232-9. PubMed ID: 11292745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional plasticity of the LACK-reactive Vbeta4-Valpha8 CD4(+) T cells normally producing the early IL-4 instructing Th2 cell development and susceptibility to Leishmania major in BALB / c mice.
    Maillard I; Launois P; Himmelrich H; Acha-Orbea H; Diggelmann H; Locksley RM; Louis JA
    Eur J Immunol; 2001 Apr; 31(4):1288-96. PubMed ID: 11298356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
    Li J; Nolan TJ; Farrell JP
    Exp Parasitol; 1997 Sep; 87(1):47-57. PubMed ID: 9287957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-18 gene therapy develops Th1-type immune responses in Leishmania major-infected BALB/c mice: is the effect mediated by the CpG signaling TLR9?
    Li Y; Ishii K; Hisaeda H; Hamano S; Zhang M; Nakanishi K; Yoshimoto T; Hemmi H; Takeda K; Akira S; Iwakura Y; Himeno K
    Gene Ther; 2004 Jun; 11(11):941-8. PubMed ID: 14985787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
    Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
    Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [LACK protein of Leishmania major: a pivotal antigen in the immune relation between host and parasite].
    Gangneux JP
    Sante; 1997; 7(6):425. PubMed ID: 9503502
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63).
    Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
    Exp Parasitol; 2009 Apr; 121(4):362-9. PubMed ID: 19211022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
    Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.